Recce Pharmaceuticals

Recce's Entitlement Offer is now live! Visit the page for instructions on how to participate

Test

Team

Home

Announcements

Updates

Lora

Managing Director and Chief Executive Officer

Recce Pharmaceuticals Ltd is a clinical-stage biotech company with a new class of unique and innovative synthetic anti-infectives currently under investigation for several indications in Phase I-Phase II clinical studies. Recce aims to revolutionise the traditional approach to medicine with their anti-infective compounds to address the global health threat of antimicrobial-resistance.

Recce’s focus is on the development of anti-infective agents for difficult to-treat bacterial and viral infections (those with unmet medical needs) using propriety synthetic polymer technology.

Recce’s synthetic broad-spectrum anti-infectives:

•  Purposely designed to overcome the hypercellular mutation of bacteria, including superbug forms; maintains its activity even with repeated use.

•  Novel Mechanism of Action (MoA): in-vitro testing indicates a unique MoA targeting both bacterial cell membrane viability and intracellular energy production, active against both growing and non-growing (stationary) bacteria.

•  Not derived from nature, no pre-formed natural superbugs.

Recce’s anti-infective pipeline includes:

•  RECCE® 327 (lead candidate) as an intravenous and topical therapy for the treatment of serious and potentially life-threatening infections due to Gram-positive and Gram-negative bacteria including their superbug forms.

•  RECCE® 435 as an orally administered therapy for bacterial infections; and RECCE® 529 for viral infections. 

We appreciate your interest in Recce, and we're excited to share our journey of healthcare innovation with you.